A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis.
about
Treatment for cramps in amyotrophic lateral sclerosis/motor neuron diseaseA comprehensive review of amyotrophic lateral sclerosisItem response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Progress in therapy development for amyotrophic lateral sclerosisErythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.Intraspinal stem cell transplantation for amyotrophic lateral sclerosisA randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progressionGacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis.Emerging drugs for amyotrophic lateral sclerosis.Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis.ALS Untangled No. 20: the Deanna protocol.Drugs in clinical development for the treatment of amyotrophic lateral sclerosis.Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Assessment of Motor Units in Neuromuscular Disease.A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.Altered Functionality, Morphology, and Vesicular Glutamate Transporter Expression of Cortical Motor Neurons from a Presymptomatic Mouse Model of Amyotrophic Lateral Sclerosis.Do We Have a Channel Solution for ALS?A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.Motoneuron Disease: Clinical.Multifactorial Gene Therapy Enhancing the Glutamate Uptake System and Reducing Oxidative Stress Delays Symptom Onset and Prolongs Survival in the SOD1-G93A ALS Mouse Model.Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology.Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.CDP-choline is not protective in the SOD1-G93A mouse model of ALS
P2860
Q24200285-B7B76A7D-3788-4E62-ABE2-4CEAA1631EFBQ26775401-6E76D966-1A87-46AB-A146-F69CBC792BADQ30488429-FB1AF208-0FFC-486E-9DCA-472CE645CADFQ34401653-7F9F6F93-F558-4377-A103-981C9BEAFFEDQ34554820-F8D31E8B-D1A2-4735-B424-0E630ECA2F83Q34640800-62636CAC-E1FA-4C21-8017-145E767F9404Q35891811-E235FE94-70B3-4CCE-BFEC-CF82DEFBD380Q36437641-F1C2FD96-ADA3-4758-87B6-C1BCC3DD4ECBQ36679757-E9B3CF2A-1EA7-410D-9022-7190558ED62EQ36813236-2627622E-04F3-45BE-9D59-A525BEFDA51FQ37415516-CAB7F9F4-B9EA-43E2-B52A-CF5E40B8C2BCQ37909351-093E3DB4-6B2B-461B-B9E7-90A15ED1F48EQ37981224-92F94EF3-A0D6-44BC-9B76-DADA5BDFDAB2Q38103571-50D32F37-5484-40BB-A129-5AA7A5D73396Q38748144-D45F07C1-0D97-423C-BB56-88F188A514DEQ38847200-8452A67A-A338-4EF7-B155-31971DE2AF12Q38881707-AB0BDA93-BDB0-4337-A0B5-0FD0EF750B49Q38947718-F2BA753E-9595-4A2E-A020-160440D15B6CQ39008917-7AF1D2FB-574F-4DC0-9646-31A5D7654B29Q41570562-B7EB3DD1-DF13-4B03-9124-C826253D93AAQ42225104-2E5F5983-14DF-409F-80B7-0EC94C668746Q42907840-3E632D24-5198-420F-885D-B01AC09BD669Q45869420-5670AF38-3313-4A53-8AFC-809193F76A41Q45881781-8B92B475-B9EA-4338-8948-97A72F30AA5CQ48377420-C12087CA-6B68-403C-824C-F86412394195Q49905442-E4824D75-D307-47CE-8FD7-19B317566F78Q54293402-EC7376F2-2B14-4935-89E9-872329F56E08Q58181343-D37F538A-0536-4DA9-AE7E-FEDCBB3FF3AD
P2860
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@en
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@nl
type
label
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@en
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@nl
prefLabel
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@en
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@nl
P2093
P2860
P50
P921
P1476
A randomized, placebo-controll ...... amyotrophic lateral sclerosis.
@en
P2093
Bemjamim Ohana
João Costa
Teresinha Evangelista
P2860
P304
P356
10.3109/17482968.2010.498521
P577
2010-10-01T00:00:00Z